Hui‐Chiu Chang

2.8k citations
52 papers · 2.4k indexed · h-index 31
Topics
Inflammatory mediators and NSAID effects (10 papers)Protease and Inhibitor Mechanisms (9 papers)Peptidase Inhibition and Analysis (8 papers)
Partner nations
Taiwan

In The Last Decade

Hui‐Chiu Chang

52 papers receiving 2.3k citations

Peers

Hui‐Chiu Chang
Comparison fields: 5 of 120
  • Molecular Biology 1.3k
  • Oncology 555
  • Cancer Research 453
  • Spectroscopy 294
  • Pharmacology 235
Replace Curtis L. Ashendel with:
Curtis L. Ashendel United States
Lijun Yang China
Claudia Escher Germany
Peter J. Wirth United States
Dipak Datta India
Stéphane Manenti France
S.C. Brooks United States
H. Grunicke Austria
Mauro Salvi Italy
Hans Adomat Canada
Hui‐Chiu Chang relative to Curtis L. Ashendel United States Curtis L. Ashendel's profile →
Citations per field
00.5×3.7×
Curtis L. Ashendel · 1×
Citations per year

Countries citing papers authored by Hui‐Chiu Chang

Since Specialization
Citations

This map shows the geographic impact of Hui‐Chiu Chang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hui‐Chiu Chang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hui‐Chiu Chang more than expected).

Fields of papers citing papers by Hui‐Chiu Chang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hui‐Chiu Chang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hui‐Chiu Chang. The network helps show where Hui‐Chiu Chang may publish in the future.

Co-authorship network of co-authors of Hui‐Chiu Chang

This figure shows the co-authorship network connecting the top 25 collaborators of Hui‐Chiu Chang. A scholar is included among the top collaborators of Hui‐Chiu Chang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hui‐Chiu Chang. Hui‐Chiu Chang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 98
2 26
3 94
4 32
5 61
6 15
7 42
8 27
9 50
10 21
11 45
12 26
13 37
14 20
15 55
16 12
17 59
18 65
19 46
20 21

About Hui‐Chiu Chang

Hui‐Chiu Chang is a scholar working on Cancer Research, Pharmacology and Oncology, having authored 52 papers that have together received 2.4k indexed citations. Recurring topics across this work include Inflammatory mediators and NSAID effects (10 papers), Protease and Inhibitor Mechanisms (9 papers) and Peptidase Inhibition and Analysis (8 papers). The work is most often cited by research in Cancer Research (453 citations), Oncology (555 citations) and Molecular Biology (1.3k citations). Hui‐Chiu Chang has collaborated with scholars based in Taiwan. Frequent co-authors include Wen‐Chun Hung, Li‐Teh Liu, Lea‐Yea Chuang, Jentaie Shiea, Mei‐Ren Pan, Wei‐Lung Tseng, Ming‐Chuan Hsu, Lien‐Chai Chiang, Chun‐Yu Cho and Ming‐Feng Hou. Their work appears in journals such as Journal of Biological Chemistry, Analytical Chemistry and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026